Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cue Biopharma, Inc is a biotechnology business based in the US. Cue Biopharma shares (CUE) are listed on the NASDAQ and all prices are listed in US Dollars. Cue Biopharma employs 45 staff and has a trailing 12-month revenue of around USD$3.7 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$13.04 |
---|---|
52-week range | USD$9.3 - USD$31.69 |
50-day moving average | USD$12.829 |
200-day moving average | USD$17.3859 |
Wall St. target price | USD$31.17 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-2.197 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $13.04 from 2020-12-09
1 week (2021-01-07) | 0.54% |
---|---|
1 month (2020-12-17) | 1.09% |
3 months (2020-10-15) | -14.99% |
6 months (2020-07-15) | -40.83% |
1 year (2020-01-15) | -17.88% |
---|---|
2 years (2019-01-15) | 138.83% |
3 years (2018-01-13) | N/A |
5 years (2016-01-13) | N/A |
Revenue TTM | USD$3.7 million |
---|---|
Gross profit TTM | USD$-24,029,154 |
Return on assets TTM | -35.47% |
Return on equity TTM | -74.36% |
Profit margin | 0% |
Book value | $2.894 |
Market capitalisation | USD$397.3 million |
TTM: trailing 12 months
There are currently 2.9 million Cue Biopharma shares held short by investors – that's known as Cue Biopharma's "short interest". This figure is 0.8% down from 2.9 million last month.
There are a few different ways that this level of interest in shorting Cue Biopharma shares can be evaluated.
Cue Biopharma's "short interest ratio" (SIR) is the quantity of Cue Biopharma shares currently shorted divided by the average quantity of Cue Biopharma shares traded daily (recently around 270917.53554502). Cue Biopharma's SIR currently stands at 10.55. In other words for every 100,000 Cue Biopharma shares traded daily on the market, roughly 10550 shares are currently held short.
However Cue Biopharma's short interest can also be evaluated against the total number of Cue Biopharma shares, or, against the total number of tradable Cue Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cue Biopharma's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Cue Biopharma shares in existence, roughly 90 shares are currently held short) or 0.0909% of the tradable shares (for every 100,000 tradable Cue Biopharma shares, roughly 91 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cue Biopharma.
Find out more about how you can short Cue Biopharma stock.
We're not expecting Cue Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Cue Biopharma's shares have ranged in value from as little as $9.3 up to $31.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cue Biopharma's is 1.9874. This would suggest that Cue Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases, as well as a strategic research collaboration with Dr. Michael Dustin and Oxford University. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.